Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

Steve Ubl built PhRMA into a more aggressive operation, one that has tangled with President Donald Trump as he seeks to curb ...

By Sneha S K and Sriparna Roy April 8 (Reuters) - Activist investor Shah Capital plans to vote against the re-election of ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

One of the world’s largest biotech companies is closing its only office in the Bay Area. Pfizer is shutting down its office ...

On the second trading day of the week, Pfizer ( PFE 2.62%) was a laggard on the stock exchange. An analyst reiterated his ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate ...

One of the most puzzling stocks these days is Pfizer ( PFE 3.40%). Although it's not generating tons of money from its COVID ...

An advance in vaccine technology is showing promise toward fighting the second-most common cause of death in the United States, cancer. Scientists are working on developing mRNA vaccines that would ...